Brexpiprazole
- Generic Name
- Brexpiprazole
- Brand Names
- Rxulti, Rexulti
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27N3O2S
- CAS Number
- 913611-97-9
- Unique Ingredient Identifier
- 2J3YBM1K8C
- Background
Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to aripiprazole, brexpiprazole has different binding affinities for dopamine and seroton...
- Indication
Brexpiprazole is indicated as adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults. It is also indicated for the treatment of schizophrenia in patients 13 years of age and older.
...
- Associated Conditions
- Agitation, Schizophrenia, Major Depressive Disorder (MDD)
- Associated Therapies
- -
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
- Conditions
- Interventions
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 1986
- Registration Number
- NCT01838681
- Locations
- 🇺🇦
UA007, Kherson,Vil. Stepanivka, Ukraine
🇺🇦UA005, Lviv, Ukraine
🇩🇪DE004, Nuernberg, Germany
Brexpiprazole in Patients With Schizophrenia
- First Posted Date
- 2013-03-14
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 210
- Registration Number
- NCT01810783
- Locations
- 🇺🇸
US004, Kissimmee, Florida, United States
🇺🇸US013, Dallas, Texas, United States
🇺🇦UA009, Lviv, Ukraine
Brexpiprazole in Patients With Acute Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 468
- Registration Number
- NCT01810380
- Locations
- 🇺🇸
US009, Escondido, California, United States
A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
- Conditions
- Interventions
- First Posted Date
- 2012-11-16
- Last Posted Date
- 2018-06-08
- Target Recruit Count
- 2182
- Registration Number
- NCT01727726
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
- First Posted Date
- 2012-08-22
- Last Posted Date
- 2016-02-04
- Target Recruit Count
- 18
- Registration Number
- NCT01670279
- Locations
- 🇺🇸
Accurate Clinical Trials, Kissimmee, Florida, United States
🇺🇸Miami Jewish Health System, Miami, Florida, United States
🇺🇸St. Louis Clinical Trials, St. Louis, Missouri, United States
Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2017-01-13
- Target Recruit Count
- 524
- Registration Number
- NCT01668797
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.